STAT+: What Baby KJ means for the CRISPR gene editing industry
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
For the ailing gene editing industry, hope came earlier this month in the tiny, smiling, fuzzy-headed form of KJ Muldoon.<\/p>\n
At just 6 months old, KJ received a gene editing treatment<\/a> custom-built to correct his unique mutation. He\u2019s not cured, researchers explained at the annual American Society of Gene & Cell Therapy meeting in New Orleans. But he has been able to resume a normal diet and is no\u00a0longer on the path to a liver transplant.\u00a0<\/p>\n The news could not have come at a more welcome or more jarring time for the field. For three years, gene editing has seemed in free fall<\/a>, riven by layoffs, closures, shuttered programs, and sinking stock prices.\u00a0Now here, finally, in striped pajama form, was a reminder of what a decade of advances could deliver. \u201cHow awesome is it that we\u2019re at this point?\u201d said Nessan Bermingham, who co-founded and led Intellia, one of the first CRISPR companies, until 2017.\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n